Oral Genome Company Profile

Background

Overview

Oral Genome is a health and wellness company specializing in dental diagnostics through innovative salivary testing. Founded in 2021 and headquartered in Carlsbad, California, the company focuses on providing personalized oral health insights to both consumers and dental professionals. By analyzing saliva samples, Oral Genome aims to detect oral diseases early and assess risks for systemic conditions, thereby promoting preventive care and overall health optimization.

Mission and Vision

Oral Genome's mission is to revolutionize oral healthcare by integrating advanced salivary diagnostics into routine dental practices, enabling early detection and personalized prevention strategies. The company's vision is to bridge the gap between dental and medical care, fostering a holistic approach to health that emphasizes prevention and proactive management.

Industry Significance

In the evolving landscape of healthcare, Oral Genome stands out by leveraging non-invasive salivary testing to provide actionable health insights. This approach aligns with the growing emphasis on preventive medicine and personalized care, positioning Oral Genome as a significant player in the dental diagnostics sector.

Key Strategic Focus

Core Objectives

Early Detection: Utilize salivary biomarkers to identify oral diseases and systemic health risks at their nascent stages.

Personalized Care: Offer tailored health recommendations based on individual salivary profiles.

Integration of Dental and Medical Care: Facilitate seamless collaboration between dental and medical professionals to enhance patient outcomes.

Areas of Specialization

Salivary Diagnostics: Develop and provide saliva-based test kits for detecting oral health conditions and assessing risks for systemic diseases.

Preventive Healthcare: Promote proactive health management through early detection and personalized prevention plans.

Key Technologies Utilized

Salivary Biomarker Analysis: Employ advanced assays to detect specific biomarkers indicative of oral and systemic health conditions.

Mobile Integration: Utilize smartphone-compatible test kits that deliver clinical-grade results in under 15 minutes without the need for lab processing.

Primary Markets Targeted

Dental Professionals: Equip dentists and hygienists with tools for chairside diagnostics and personalized patient care.

Consumers: Provide individuals with accessible at-home testing options to monitor and manage their oral health.

Healthcare Providers: Support medical practitioners in identifying oral-systemic health risks and facilitating early interventions.

Financials and Funding

Funding History

Oral Genome has successfully completed multiple seed funding rounds, raising a total of approximately $3.23 million. Notable investors include Plug and Play and Health Wildcatters.

Recent Funding Round

Date: March 3, 2025

Amount Raised: $3.1 million

Lead Investors: Plug and Play

Utilization of Capital

The funds are intended to support product development, expand market reach, and enhance research and development efforts to advance salivary diagnostic technologies.

Pipeline Development

Key Pipeline Candidates

Salivary Test Kits: Point-of-care saliva test kits that provide real-time insights into oral and systemic health.

Stages of Development

Product Development: Ongoing refinement of test kits to improve accuracy, ease of use, and integration with mobile platforms.

Clinical Validation: Conducting studies to validate the efficacy and reliability of salivary biomarkers in detecting various health conditions.

Target Conditions

Oral Diseases: Cavities, periodontal disease, and other oral health issues.

Systemic Health Risks: Conditions such as diabetes and cardiovascular diseases that have oral health implications.

Anticipated Milestones

Product Launches: Introduction of enhanced test kits with expanded biomarker panels.

Regulatory Approvals: Achieving necessary certifications and approvals for broader market distribution.

Technological Platform and Innovation

Proprietary Technologies

Salivary Biomarker Assays: Developed assays that detect specific biomarkers linked to oral and systemic health conditions.

Mobile Integration: Smartphone-compatible test kits that deliver clinical-grade results in under 15 minutes without the need for lab processing.

Significant Scientific Methods

Biomarker Analysis: Utilizing advanced assays to identify biomarkers indicative of oral and systemic health conditions.

Image Processing and Machine Learning: Employing machine learning algorithms to interpret test results accurately using smartphone cameras.

Leadership Team

Key Executives

Dr. Tina Saw, DDS – CEO and Founder

Background: A general dentist and serial entrepreneur with over 15 years in the dental industry.

Contributions: Founded Oral Genome to integrate advanced diagnostics into dental care, emphasizing preventive health.

Deborah Liu – Chief Technology Officer

Background: Experience in biotechnology and health technology sectors.

Contributions: Oversees the development of diagnostic technologies and integration with mobile platforms.

Kim Kutsch, DMD – Chief Medical Officer

Background: Extensive experience in dental medicine and clinical research.

Contributions: Guides the clinical validation of diagnostic tests and ensures alignment with dental practice standards.

Leadership Changes

As of April 2026, there have been no publicly disclosed significant changes or appointments within Oral Genome's leadership team.

Competitor Profile

Market Insights and Dynamics

The dental diagnostics market is experiencing growth driven by the increasing emphasis on preventive care and personalized medicine. Salivary diagnostics, in particular, are gaining traction due to their non-invasive nature and potential for early disease detection.

Competitor Analysis

OralDNA Labs

Focus: Saliva-based tests for periodontal disease and infections.

Notable Achievements: Developed products like MyPerioPath and OraRisk HPV.

Competitive Landscape: Operates in a competitive market with competitors including Prenetics, Inflammatix, Karius, Day Zero Diagnostics, and MeMed.

Prenetics

Focus: Health risk identification through online genetic and diagnostic testing.

Competitive Landscape: Competes in the health diagnostics sector with a focus on genetic testing.

Karius

Focus: Non-invasive pathogen blood tests for infectious diseases.

Competitive Landscape: Operates in the diagnostics market with a focus on infectious diseases.

Strategic Collaborations and Partnerships

Henry Schein Partnership

Description: In August 2025, Oral Genome partnered with Henry Schein to expand the use of salivary testing in dental and medical offices.

American Dental Association (ADA) Investment

Description: In March 2024, Oral Genome secured an investment from the ADA, marking the association's first investment in a company.

Operational Insights

Oral Genome differentiates itself through its focus on non-invasive salivary diagnostics, offering quick, chairside testing that integrates seamlessly into dental practices. The company's partnerships with industry leaders like Henry Schein and the ADA enhance its market position and credibility.

Strategic Opportunities and Future Directions

Market Expansion: Leverage partnerships to expand the adoption of salivary diagnostics in dental and medical practices nationwide.

Product Development: Enhance test kits with additional biomarkers and improve integration with mobile health platforms.

Research and Validation: Conduct further clinical studies to validate the efficacy of salivary diagnostics in detecting a broader range of health conditions.